Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...
In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...
Asianet Newsable on MSN
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug
Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the ...
Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...
Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...
Agios Pharmaceuticals (AGIO) stock falls as a late-stage trial for its lead drug mitapivat in sickle cell disease indicate a ...
Agios Pharmaceuticals said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but failed to show a statistically significant ...
Agios Pharmaceuticals Inc. reported top-line data from its 52-week Rise Up trial testing oral pyruvate kinase activator mitapivat in sickle cell disease (SCD), which hit statistical significance on ...
Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback